EA201691330A1 - Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы - Google Patents
Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазыInfo
- Publication number
- EA201691330A1 EA201691330A1 EA201691330A EA201691330A EA201691330A1 EA 201691330 A1 EA201691330 A1 EA 201691330A1 EA 201691330 A EA201691330 A EA 201691330A EA 201691330 A EA201691330 A EA 201691330A EA 201691330 A1 EA201691330 A1 EA 201691330A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- haa
- xaa
- diseases
- infections
- elastase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 102000016387 Pancreatic elastase Human genes 0.000 abstract 2
- 108010067372 Pancreatic elastase Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 239000000816 peptidomimetic Substances 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000052502 human ELANE Human genes 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/078073 WO2015096873A1 (en) | 2013-12-27 | 2013-12-27 | Beta-hairpin peptidomimetics as selective elastase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201691330A1 true EA201691330A1 (ru) | 2016-10-31 |
Family
ID=49911533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201691330A EA201691330A1 (ru) | 2013-12-27 | 2013-12-27 | Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10273267B2 (enExample) |
| EP (1) | EP3087094B1 (enExample) |
| JP (1) | JP6499183B2 (enExample) |
| KR (1) | KR102214694B1 (enExample) |
| CN (1) | CN106029689B (enExample) |
| AU (1) | AU2013409200B2 (enExample) |
| BR (1) | BR112016014916B1 (enExample) |
| CA (1) | CA2933660C (enExample) |
| DK (1) | DK3087094T3 (enExample) |
| EA (1) | EA201691330A1 (enExample) |
| ES (1) | ES2925747T3 (enExample) |
| HR (1) | HRP20221046T1 (enExample) |
| HU (1) | HUE059846T2 (enExample) |
| IL (1) | IL246175B (enExample) |
| LT (1) | LT3087094T (enExample) |
| MX (1) | MX389053B (enExample) |
| NZ (1) | NZ722025A (enExample) |
| PL (1) | PL3087094T3 (enExample) |
| PT (1) | PT3087094T (enExample) |
| RS (1) | RS63543B1 (enExample) |
| SG (1) | SG11201605122WA (enExample) |
| SI (1) | SI3087094T1 (enExample) |
| SM (1) | SMT202200393T1 (enExample) |
| WO (1) | WO2015096873A1 (enExample) |
| ZA (1) | ZA201604821B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0721259C1 (pt) | 2007-02-28 | 2021-05-25 | Polyphor Ltd | composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto |
| CN105873939B (zh) * | 2013-12-27 | 2021-08-27 | 波利弗尔股份公司 | 作为选择性弹性蛋白酶抑制剂的β-发夹肽模拟物 |
| US10676723B2 (en) * | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| SG11201802777XA (en) | 2015-10-14 | 2018-05-30 | X Therma Inc | Compositions and methods for reducing ice crystal formation |
| ES2928050T3 (es) | 2016-05-31 | 2022-11-15 | Spexis Ag | Peptidomimético de horquilla beta con actividad inhibidora de elastasa y formas de dosificación en aerosol del mismo |
| BR112022004861A2 (pt) | 2019-09-17 | 2022-06-07 | Univ Duke | Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro |
| US20230190723A1 (en) | 2020-04-16 | 2023-06-22 | Mereo Biopharma 4 Limited | Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency |
| CN114573686A (zh) * | 2020-11-30 | 2022-06-03 | 中国医学科学院药物研究所 | 含有二硫键且具有抑制丝氨酸蛋白酶活性的多肽及其应用 |
| AU2022373971A1 (en) | 2021-10-20 | 2024-04-04 | Mereo Biopharma 4 Limited | Neutrophil elastase inhibitors for use in the treatment of fibrosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| GB9825854D0 (en) | 1998-11-25 | 1999-01-20 | Univ Bristol | Peptide |
| CN101157924A (zh) | 2001-12-11 | 2008-04-09 | 人体基因组科学有限公司 | 嗜中性白细胞因子α |
| CA2915175C (en) * | 2005-02-17 | 2019-04-09 | Polyphor Ltd. | Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity |
| CN105873939B (zh) * | 2013-12-27 | 2021-08-27 | 波利弗尔股份公司 | 作为选择性弹性蛋白酶抑制剂的β-发夹肽模拟物 |
-
2013
- 2013-12-27 HR HRP20221046TT patent/HRP20221046T1/hr unknown
- 2013-12-27 BR BR112016014916-5A patent/BR112016014916B1/pt not_active IP Right Cessation
- 2013-12-27 CA CA2933660A patent/CA2933660C/en active Active
- 2013-12-27 WO PCT/EP2013/078073 patent/WO2015096873A1/en not_active Ceased
- 2013-12-27 US US15/107,575 patent/US10273267B2/en active Active
- 2013-12-27 PT PT138155270T patent/PT3087094T/pt unknown
- 2013-12-27 NZ NZ722025A patent/NZ722025A/en not_active IP Right Cessation
- 2013-12-27 PL PL13815527.0T patent/PL3087094T3/pl unknown
- 2013-12-27 SM SM20220393T patent/SMT202200393T1/it unknown
- 2013-12-27 DK DK13815527.0T patent/DK3087094T3/da active
- 2013-12-27 EP EP13815527.0A patent/EP3087094B1/en active Active
- 2013-12-27 CN CN201380082026.9A patent/CN106029689B/zh not_active Expired - Fee Related
- 2013-12-27 KR KR1020167020452A patent/KR102214694B1/ko not_active Expired - Fee Related
- 2013-12-27 SG SG11201605122WA patent/SG11201605122WA/en unknown
- 2013-12-27 ES ES13815527T patent/ES2925747T3/es active Active
- 2013-12-27 MX MX2016008318A patent/MX389053B/es unknown
- 2013-12-27 EA EA201691330A patent/EA201691330A1/ru unknown
- 2013-12-27 LT LTEPPCT/EP2013/078073T patent/LT3087094T/lt unknown
- 2013-12-27 HU HUE13815527A patent/HUE059846T2/hu unknown
- 2013-12-27 AU AU2013409200A patent/AU2013409200B2/en not_active Ceased
- 2013-12-27 JP JP2016543043A patent/JP6499183B2/ja not_active Expired - Fee Related
- 2013-12-27 SI SI201332006T patent/SI3087094T1/sl unknown
- 2013-12-27 RS RS20220817A patent/RS63543B1/sr unknown
-
2016
- 2016-06-13 IL IL246175A patent/IL246175B/en unknown
- 2016-07-13 ZA ZA2016/04821A patent/ZA201604821B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691330A1 (ru) | Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы | |
| EA201591751A1 (ru) | Трипептидные эпоксикетонные ингибиторы протеазы | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| DOP2015000240A (es) | 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| EA201790595A1 (ru) | Пиримидиноны в качестве ингибиторов фактора xia | |
| MX375674B (es) | Compuestos de carboxamida inhibidores de la actividad de cinasa rip2. | |
| NZ719905A (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| TR201905814T4 (tr) | Jak inhibitörü olarak bipirazol tuzu. | |
| EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
| EA201791507A1 (ru) | Пирроло- и пиразолопиримидины в качестве ингибиторов убиквитин- специфичной протеазы 7 | |
| JO3326B1 (ar) | مثبطات إيبوكسي كيتون بروتياز ثلاثي الببتيد | |
| UA109667C2 (xx) | Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази | |
| EA201691328A1 (ru) | Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы | |
| EA201792028A1 (ru) | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 | |
| WO2016100347A3 (en) | Small molecule inhibitors of egfr and pi3k | |
| EA201790660A1 (ru) | Ингибитор киназ | |
| EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
| MX381230B (es) | Novedoso compuesto de 1,2,4-triazina disustituida. | |
| EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
| EA201690386A1 (ru) | Соединения и композиции в качестве ингибиторов mek | |
| EA201291038A1 (ru) | Соединения пиразола в качестве ингибиторов jak | |
| CY1125179T1 (el) | Παραγωγα πυραζολιου χρησιμα ως αναστολεις της πρωτεïνης ενεργοποιησης της 5-λιποξυγενασης (flap) | |
| BR112019001980A2 (pt) | inibidor de ido1 e método de preparação e aplicação do mesmo | |
| EA201591379A1 (ru) | Липопротеин-ассоциированные ингибиторы фосфолипазы a2 (lp-pla) на основе 2,3-дигидроимидазо[1,2-с]пиримидин-5(1h)-онов |